• Earlier in March 2026, BIO-key International announced a partnership with TD SYNNEX Public Sector (DLT Solutions) to distribute its PortalGuard IAM and Passkey:YOU biometric security tools across U.S. federal, state, and local government contracts.
• This move deepens TD SYNNEX’s reach in government-focused cybersecurity and identity management, aligning its distribution platform with compliance-heavy markets like CJIS, HIPAA, and NIST SP 800-171.
• We’ll now examine how TD SYNNEX’s stronger-than-expected quarterly results and expanded public sector security offerings may affect its investment narrative.

The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

TD SYNNEX Investment Narrative Recap

To own TD SYNNEX, you need to believe it can keep turning its global IT distribution scale into steady earnings while adapting to cloud, AI, and services-heavy demand. The BIO-key public sector partnership and stronger-than-expected recent quarter both support the near term catalyst around higher value software and cybersecurity mix, but they do not materially change the key risk that demand may soften if earlier purchase pull forwards unwind.

The BIO-key deal is especially relevant because it deepens TD SYNNEX’s role in cybersecurity and identity management for highly regulated U.S. government customers, tying directly into its public sector growth catalyst. It also complements the recent SCAILIUM AI Production Layer partnership, which targets more complex, service-rich deployments that may help counter long term pressure on traditional hardware distribution volumes.

Yet while these wins broaden TD SYNNEX’s reach, investors should still be aware that...

TD SYNNEX's narrative projects $66.8 billion revenue and $914.7 million earnings by 2028.

Uncover how TD SYNNEX's forecasts yield a $179.73 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Two members of the Simply Wall St Community currently see TD SYNNEX’s fair value between US$179.73 and US$248.67, well above the recent share price. Against that backdrop, the risk that prior demand pull forwards could lead to softer revenue growth later on becomes an important piece of the story that readers should weigh alongside their own expectations.

Explore 2 other fair value estimates on TD SYNNEX - why the stock might be worth as much as 63% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your TD SYNNEX research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free TD SYNNEX research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate TD SYNNEX's overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.